MOUSE ANTI-HEPATITIS B VIRUS E ANTIGEN ANTIBODY (1892)
Mouse anti HBeAg antibody (clone 1892) is specific for Hepatitis B virus. The HBeAg antibody is suitable for immunoassay research and development. Clone 1892 is suitable for use as a capture antibody with either clone 1893 (MAB12227) or clone 1894 (MAB12228) in ELISA assays.
PRODUCT DETAILS – MOUSE ANTI-HEPATITIS B VIRUS E ANTIGEN ANTIBODY (1892)
- Mouse anti-Hepatitis B virus E antigen monoclonal IgG1 antibody (clone 1892).
- Greater than 90% purity by SDS-PAGE and buffered in PBS, pH7.4.
Hepatitis B virus (HBV) is a small, partially double-stranded DNA virus that belongs to the genus Orthohepadnaviruses of the Hepadnaviridae family of viruses. Currently, eight genotypes of HBV are recognised, designated A-H, with each genotype having a distinct geographical distribution. HBV is a retrovirus that replicates by reverse transcription of an RNA intermediate. HBV encodes seven proteins, recognised as preCore, core, pol, X (HBx), and envelope proteins L, M and S (Liang ,TJ).
HBV is a bloodborne virus that is transmitted through contact with infected blood or bodily fluids. HBV infection may occur through various routes including the sharing of needles for injecting drugs, the use of inadequately sterilised medical equipment infected with HBV and the transfusion of unscreened blood and blood products. In endemic areas, perinatal transmission of HBV from mother to child is common.
HBV infection causes liver disease which can vary from acute, or chronic hepatitis to cirrhosis of the liver and potentially hepatocellular carcinoma. The incubation of HBV infection can vary from 1 – 6 months. During the period of acute infection, most individuals remain asymptomatic. However, some patients develop acute illness presenting with clinical symptoms that include jaundice, nausea, vomiting, abdominal pain and extreme fatigue. Acute liver failure may occur in 1% of patients, which can be fatal. HBV infected patients may also develop chronic lifelong disease, which can progress to cirrhosis or hepatocellular carcinoma in 20-30% of adult cases (WHO).
The asymptomatic nature of HBV infection, and the similarity of clinical symptoms to other types of hepatitis virus infection makes clinical diagnosis difficult. Therefore, laboratory diagnosis is undertaken using serological and molecular methods to detect HBsAg and specific IgM antibodies recognising core antigen HbcAg.